Buy CRDL by Oct 11, 2026.

One thing I have learned with biotech is that the big move often starts before the actual data, not after. By the time the readout arrives, the market has usually already started sorting the names into buckets: ignored science project, funded late-stage setup, or legitimate strategic asset. CRDL looks like it is trying to move into that second bucket. The company has runway into Q4 2027, patent protection into late 2040, Phase 3 enrollment >75% with topline data expected in …